DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D, Gothelf D, Nahshoni E, Tyano S, Weizman A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European Neuropsychopharmacology 2003, 13: 183-185. PMID: 12729944, DOI: 10.1016/s0924-977x(03)00006-3.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePossible associationAdolescent schizophrenia patientsFirst-episode schizophreniaPsychiatric Rating ScaleHigh response rateClinical responseRepeat alleleSchizophrenia patientsResponse rateSignificant associationPharmacogenetic studiesRisperidoneAdolescent inpatientsRating ScaleSchizophreniaAssociationDRD4 genotypeDRD4 geneResponseIsraeli adolescentsLarge groupPolymorphismDRD4 exon III polymorphismPatients